Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective multicenter non-interventional study of apatinib in advanced gastric cancer
ChiCTR-OPN-15006601Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jul 2015
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Safety. Started Jul 2015; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR-OPN-15006601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-15006601.